Who Is a Typical Patient with Visceral Leishmaniasis? Characterizing the Demographic and Nutritional Profile of Patients in Brazil, East Africa, and South Asia

Hdl Handle:
http://hdl.handle.net/10144/141430
Title:
Who Is a Typical Patient with Visceral Leishmaniasis? Characterizing the Demographic and Nutritional Profile of Patients in Brazil, East Africa, and South Asia
Authors:
Harhay, Michael O; Olliaro, Piero L; Vaillant, Michel; Chappuis, François; Lima, María Angeles; Ritmeijer, Koert; Costa, Carlos Henrique; Costa, Dorcas Lamounier; Rijal, Suman; Sundar, Shyam; Balasegaram, Manica
Journal:
The American Journal of Tropical Medicine and Hygiene
Abstract:
Abstract. Drug-dosing recommendations for visceral leishmaniasis (VL) treatment are based on the patients' weight or age. A current lack of demographic and anthropometric data on patients hinders (1) the ability of health providers to properly prepare for patient management, (2) an informed drug procurement for disease control, and (3) the design of clinical trials and development of new drug therapies in the different endemic areas. We present information about the age, gender, weight, and height of 29,570 consecutive VL patients presenting to 20 locations in six geographic endemic regions of Brazil, East Africa, Nepal, and India between 1997 and 2009. Our compilation shows substantial heterogeneity in the types of patients seeking care for VL at the clinics within the different locations. This suggests that drug development, procurement, and perhaps even treatment protocols, such as the use of the potentially teratogenic drug miltefosine, may require distinct strategies in these geographic settings.
Affiliation:
Graduate Group in Demography, University of Pennsylvania, Philadelphia, Pennsylvania; United Nations Children's Fund/United Nations Development Programme/World Bank/World Health Organization Special Programme for Research and Training in Tropical Diseases (TDR), Geneva, Switzerland; Centre for Tropical Medicine, University of Oxford, Oxford, United Kingdom; Clinical Epidemiology and Public Health Unit, Center for Health Studies, Centre de Recherche Publique (CRP-Santé), Luxembourg; Médecins Sans Frontières, Operational Centre Geneva (MSF-OCG), Geneva, Switzerland; Division of International and Humanitarian Medicine, Geneva University Hospitals and University of Geneva, Geneva, Switzerland; Médecins Sans Frontières, Operational Centre Barcelona-Athens (MSF-OCBA), Barcelona, Spain; Médecins Sans Frontières, Operational Centre Amsterdam (MSF-OCA), Amsterdam, The Netherlands; Instituto de Doenças Tropicais Natan Portella, Teresina, Piauí, Brazil; Federal University of Piauí, Piauí, Brazil; Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Department of Internal Medicine, B. P. Koirala Institute of Health Sciences, Dharan, Nepal; Institute of Medical Sciences, Banaras Hindu University, Varanasi, India; Drugs for Neglected Diseases Initiative (DNDi), Geneva, Switzerland
Issue Date:
1-Apr-2011
URI:
http://hdl.handle.net/10144/141430
DOI:
10.4269/ajtmh.2011.10-0321
PubMed ID:
21460007
Additional Links:
http://www.ajtmh.org/cgi/content/abstract/84/4/543
Submitted date:
2011-04-29
Type:
Article
Language:
en
ISSN:
1476-1645
Appears in Collections:
Leishmaniasis/Kala Azar

Full metadata record

DC FieldValue Language
dc.contributor.authorHarhay, Michael Oen
dc.contributor.authorOlliaro, Piero Len
dc.contributor.authorVaillant, Michelen
dc.contributor.authorChappuis, Françoisen
dc.contributor.authorLima, María Angelesen
dc.contributor.authorRitmeijer, Koerten
dc.contributor.authorCosta, Carlos Henriqueen
dc.contributor.authorCosta, Dorcas Lamounieren
dc.contributor.authorRijal, Sumanen
dc.contributor.authorSundar, Shyamen
dc.contributor.authorBalasegaram, Manicaen
dc.date.accessioned2011-08-31T18:40:56Z-
dc.date.available2011-08-31T18:40:56Z-
dc.date.issued2011-04-01-
dc.date.submitted2011-04-29-
dc.identifier.citationAm J Trop Med Hyg 2011;84(4):543-550en
dc.identifier.issn1476-1645-
dc.identifier.pmid21460007-
dc.identifier.doi10.4269/ajtmh.2011.10-0321-
dc.identifier.urihttp://hdl.handle.net/10144/141430-
dc.description.abstractAbstract. Drug-dosing recommendations for visceral leishmaniasis (VL) treatment are based on the patients' weight or age. A current lack of demographic and anthropometric data on patients hinders (1) the ability of health providers to properly prepare for patient management, (2) an informed drug procurement for disease control, and (3) the design of clinical trials and development of new drug therapies in the different endemic areas. We present information about the age, gender, weight, and height of 29,570 consecutive VL patients presenting to 20 locations in six geographic endemic regions of Brazil, East Africa, Nepal, and India between 1997 and 2009. Our compilation shows substantial heterogeneity in the types of patients seeking care for VL at the clinics within the different locations. This suggests that drug development, procurement, and perhaps even treatment protocols, such as the use of the potentially teratogenic drug miltefosine, may require distinct strategies in these geographic settings.en
dc.languageENG-
dc.language.isoenen
dc.relation.urlhttp://www.ajtmh.org/cgi/content/abstract/84/4/543en
dc.rightsArchived with thanks to The American Journal of Tropical Medicine and Hygieneen
dc.subject.meshVisceral Leishmaniasisen
dc.subject.meshNutritional Statusen
dc.subject.meshDemographyen
dc.titleWho Is a Typical Patient with Visceral Leishmaniasis? Characterizing the Demographic and Nutritional Profile of Patients in Brazil, East Africa, and South Asiaen
dc.typeArticleen
dc.contributor.departmentGraduate Group in Demography, University of Pennsylvania, Philadelphia, Pennsylvania; United Nations Children's Fund/United Nations Development Programme/World Bank/World Health Organization Special Programme for Research and Training in Tropical Diseases (TDR), Geneva, Switzerland; Centre for Tropical Medicine, University of Oxford, Oxford, United Kingdom; Clinical Epidemiology and Public Health Unit, Center for Health Studies, Centre de Recherche Publique (CRP-Santé), Luxembourg; Médecins Sans Frontières, Operational Centre Geneva (MSF-OCG), Geneva, Switzerland; Division of International and Humanitarian Medicine, Geneva University Hospitals and University of Geneva, Geneva, Switzerland; Médecins Sans Frontières, Operational Centre Barcelona-Athens (MSF-OCBA), Barcelona, Spain; Médecins Sans Frontières, Operational Centre Amsterdam (MSF-OCA), Amsterdam, The Netherlands; Instituto de Doenças Tropicais Natan Portella, Teresina, Piauí, Brazil; Federal University of Piauí, Piauí, Brazil; Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; Department of Internal Medicine, B. P. Koirala Institute of Health Sciences, Dharan, Nepal; Institute of Medical Sciences, Banaras Hindu University, Varanasi, India; Drugs for Neglected Diseases Initiative (DNDi), Geneva, Switzerlanden
dc.identifier.journalThe American Journal of Tropical Medicine and Hygieneen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.